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Abstract
The autism spectrum disorders are a group of conditions with neurobehavioral impairment
affecting approximately 0.6% of children. The clinical presentation is complex and the etiology is
largely unknown, although a major role of genetic factors is widely accepted. A number of genetic
studies led to the identification of genes and/or copy number variants whose alterations are
associated with autism, but no specific factor has been found so far to be responsible for a
substantial proportion of cases. Epigenetic modifications may also play a role, as demonstrated by
the occurrence of autism in genetic conditions caused by mutations in imprinted genes or regions.
The article by Gregory et al. published this month in BMC Medicine, reports on genomic and
epigenetic alterations of OXTR, the gene encoding the receptor for oxytocin. The involvement of
this gene was suggested by its deletion in an autistic patient. The subsequent analysis of a group of
unrelated autistic subjects did not show an OXTR deletion, but rather hypermethylation of the gene
promoter, with a reduced mRNA expression.
These findings address two major points of the current debate on the etiology and pathogenesis of
autism: the role of oxytocin, known to be involved in modeling human behavior, and the possible
involvement of epigenetic mechanisms. The nature of this epigenetic dysregulation is unknown but,
if proved to be true, might explain the failure to identify sequence alterations in a host of candidate
genes. Practical implications of these findings may be forthcoming, however not before extension
and validation on a larger scale have confirmed their value.
See the associated research paper by Gregory et al: http://www.biomedcentral.com/1741-7015/7/
62
Background
This month in BMC Medicine, Gregory et al. [1] report on
a potential new clue to understanding the etiology of
autism.
The autism spectrum disorders (ASDs) are a group of neu-
rodevelopmental conditions characterized by impairment
in social, emotional and communicative skills and by ster-
eotyped motor and mental processes with an onset in the
first 3 years of life. ASD affects approximately 0.6% of
children[2]. The number of children diagnosed with this
condition has greatly increased in recent decades, likely
due to increased awareness, reduced stringency of diag-
nostic criteria and, possibly, other factors of unknown
nature [3].
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Regarding the etiology, it is generally accepted that genetic
factors play a major role and it has become clear that, with
the exception of a minority of instances (about 1%) in
which the phenotype is caused by a single gene alteration,
the genetic component leading to autism is complex,
being based on interactions of multiple genetic changes
and/or epigenetic regulation of gene expression.
Because of this complexity, decades of experimental work,
even with the aid of sophisticated molecular genetic tools
(such as high resolution total genome quantitative analy-
sis, array expression analysis or high resolution single
nucleotide polymorphism (SNP) array platforms) have
failed to identify specific causes in any substantial propor-
tion of cases [4,5]. Nonetheless, quantitative whole-
genome analyses promise to identify one or a few autism-
specific copy number variants (CNVs) harboring genes
whose dosage alterations could be critical in causing ASD.
From a number of array comparative genomic hybridiza-
tion (array CGH) studies [6], even on large cohorts of
patients, we have learnt that up to 10% of sporadic ASD
cases do show de novo CNVs, some non-randomly associ-
ated with ASD, although none of these have been so far
proven to harbor major genes causing or predisposing to
ASD.
Likewise, several biological parameters, such as the posts-
ynaptic receptor density [7,8], the intercellular adhesion
mechanisms [9,10], the immune system [11-16], some
hormonal exposures [17-22], imbalances in specific neu-
rotransmitters [23,24] and the epigenetic regulation of
gene expression [25,26] have emerged as possibly
involved in the pathogenesis of ASD.
OXTR in ASD
This month in BMC Medicine, Gregory et al. show that
there is genomic and epigenetic evidence of a reduced
function of the oxytocin receptor in autism. They identi-
fied a genomic deletion containing the gene encoding for
the oxytocin receptor (OXTR) in an autistic male individ-
ual and in his mother, who probably experienced obses-
sive-compulsive disorder (OCD). The equally affected
brother did not have the same deletion but rather a hyper-
methylation of specific CpG islands likely to cause a
reduced expression of the OXTR gene. It would be inter-
esting to know the methylation status of the OXTR allele
also in the deleted proband and in the mother, and to
measure its level of expression. Likewise, one would want
to know whether the maternal deletion was de novo or
inherited. Could the OXTR  gene be imprinted? So far
there is no evidence of a possible monoallelic, parental-
specific expression in any tissue.
Regardless, the above findings prompted the analysis of
the methylation status of the OXTR gene in a number of
samples from autistic subjects, including brain tissue from
the temporal cortex as well as peripheral blood lym-
phocytes. Although the sample is not a large one, the
authors found a hypermethylation of specific CpG islands
and a correspondingly reduced expression of the OXTR
gene. This brings up the question of how did this hyper-
methylation occur? Was it environmentally induced or
genetically determined?
The findings of Gregory et al. address two major points in
the current debate on the cause and pathogenesis of
autism: one related to the role of oxytocin and its receptor,
the other to the possible role of epigenetic mechanisms.
Regarding the former, there is growing evidence that the
oxytocin-vasopressin pathway has an influence on social
behavior both under normal circumstances and in a clin-
ical setting [19,20,27,28]. It has been reported that mice
lacking the oxytocin gene show social deficits [29], thus
strengthening the role of this nonapeptyde in modeling
individual behavior. In addition, association studies in
autistic cohorts have shown linkage with polymorphisms
in the vasopressin and OXTR genes [21,30-32]. Duplica-
tions of the 3p25-3p26 genomic region, leading to over-
expression of the OXTR gene, have been associated with a
pervasive developmental disorder in a patient with obes-
ity and behavioral issues [33], thus suggesting that
increased OXTR expression can cause behavioral pheno-
type falling within the ASD spectrum.
Epigenetic modification of OXTR
The second issue raised by Gregory et al. deals with the
epigenetic inhibition of OXTR expression in ASD. Such
epigenetic modification, at least as reported so far, does
not seem to be sequence based but rather of a different, as
yet unknown nature. This might explain why researchers
have been looking for decades for genetic mutations in
ASD and yet have found almost none. An epigenetic
mechanism would justify the 'unusual', non-Mendelian
familial aggregations of ASD. In this respect, even the fam-
ily with OXTR deficiency reported by Gregory et al. shows
an unusual genotype-phenotype correlation, in that the
same phenotype is caused by alterations of the same gene
but due to different molecular defects (deletion versus
hypermethylation).
Also, the possibility that in most ASD patients there might
be an epigenomic instability is of interest in consideration
of the fact that it has been shown that the epigenetic status
in early fetal development can be reprogrammed by
maternal behavior in a reversible way [34]. Therefore,
other environmental factors, yet to be discovered, might
also be able to reprogram the epigenotype of the embryo.
The epigenetic nature of ASD has been already suspected
based on many instances, such as the association of ASD
with conditions caused by mutations of imprinted genesBMC Medicine 2009, 7:63 http://www.biomedcentral.com/1741-7015/7/63
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like Angelman, Fragile X or Rett syndromes, or with quan-
titative alterations in regions like the 15q11-q13, also
known to be imprinted [25].
Conclusion
The findings by Gregory et al. seem to open new avenues
in the research on ASD, one involving the oxytocin path-
way, the other the human methylome. Thus, future
research in the field may take sharp turns, searching for
genetic alterations responsible for ASD beyond DNA
sequencing and into epigenetic regulation of gene func-
tion. Of course, before these findings can be applied as
diagnostic tools or biomarkers of ASD, or can even lay
down a basis for therapeutic approaches, it is necessary to
confirm them in larger cohorts of patients and controls. It
is true that in ASD replication studies have often failed,
although this should not stop us from striving to solve
this puzzle. Time and further studies will tell us whether
the results seen here live up to their initial promise.
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